# Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

> **NCT02239835** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 79 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tipranavir (TPV) low dose
- **DRUG:** Tipranavir (TPV) high dose
- **DRUG:** Ritonavir low dose
- **DRUG:** Ritonavir high dose
- **DRUG:** Saquinavir

## Key facts

- **NCT ID:** NCT02239835
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-12
- **Primary completion:** 2001-11
- **Final completion:** —
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239835, "Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02239835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*